CLINICAL VALUE OF BIOCHEMICAL MARKERS OF NEUROENDOCRINE TUMORS
نویسندگان
چکیده
منابع مشابه
Biochemical testing for neuroendocrine tumors.
In this review, we focus on the use of biochemical markers for the diagnosis of neuroendocrine tumors and exclusion of conditions that masquerade as neuroendocrine tumors. In addition, we outline the use of biochemical markers for follow-up, response to intervention, and determination of prognosis. Previous publications have focused only on markers specific to certain tumor types, but the uniqu...
متن کاملENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
aDepartment of Gastroentereology and Clinical Medicine, St. James’s Hospital and Trinity College, Dublin, Ireland; bSt. Bartholomew, West Smithfield, London, UK; cDepartment of Endocrinology and Metabolism, Hadassah University Hospital, Jerusalem, Israel; dOspedale S. Andrea, Rome, Italy; eDepartment of Oncology, University Hospital, Prague, Czech Republic; fInstituto Alexander Fleming, Buenos ...
متن کاملInvestigating the diagnostic value of tumor markers compared to ultrasound in the diagnosis of ovarian tumors
Aims: Ovarian cancer has the worst prognosis among female genital tract malignancies, but if detected in the early stages, it is one of the most treatable malignancies. The aim of this study was to investigate the diagnostic value of tumor markers compared to ultrasound in the diagnosis of ovarian tumors. Materials and methods: In this cross-sectional-analytical study, 210 women referred to ...
متن کاملPrognostic Markers in Rectal Neuroendocrine Tumors
................................................................................................................. 3 Acknowledgements ................................................................................................ 5
متن کاملClinical Neuroendocrinology and Neuroendocrine Tumors
Background/Aim: Tumors exhibiting constitutively activated PI(3)K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including neuroendocrine tumors (NETs). However, no preclinical data about the effects of RAD001 on NET cells have been published. In this study, we aime...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical academic journal
سال: 2019
ISSN: 1608-4101
DOI: 10.17816/maj191s128-29